Jefferies has maintained a 'buy' rating on AstraZeneca with a price target of 17,500p, implying a 46% upside from the current share price. The broker expects AstraZeneca's third-quarter revenue to exceed consensus by about 1%, and core earnings before interest and tax to be 3% above expectations, driven by higher alliance revenue, royalties, and lower operating costs. Despite some challenges like faster US Farxiga sales erosion and softer Lynparza volumes, Jefferies remains optimistic about AstraZeneca's lung cancer trial AVANZAR and potential catalysts from Summit Therapeutics' HARMONi-3 trial. The broker believes AstraZeneca's growth can continue beyond 2030, supported by its cancer drug portfolio and strategic investments, reiterating its buy rating with a price target valuing the stock at a premium to the European pharmaceutical sector.
AstraZeneca trades at USD 158.73 on Pluang as of Oct 07, 2026 18:11 WIB, showing a slight 0.08% increase today. The stock holds a market cap of $245.13 billion with a dividend yield of 2.02%. Pluang users currently show 100% buy interest in AstraZeneca, reflecting strong demand on the platform.
Citigroup has raised its price target for AstraZeneca to £186.00 from £178.00, maintaining a Buy rating following successful Phase 3 clinical trials. The increase reflects higher peak sales forecasts for drugs tozorakimab and SERENA-6, offsetting the...
Citi has increased its target price for AstraZeneca to £186 from £178, maintaining a 'buy' rating after positive clinical developments, especially for the drug tozorakimab. The broker raised peak sales forecasts for tozorakimab to $7 billion and SERE...
AstraZeneca announced a $2 billion equity investment and clinical collaboration with Summit Therapeutics to develop ivonescimab, a first-in-class bispecific antibody for cancer treatment. This drug targets two cancer pathways simultaneously, potentia...
